Mesenchymal stem cells - Longeveron

Drug Profile

Mesenchymal stem cells - Longeveron

Alternative Names: Allogeneic Human Mesenchymal Stem Cells; LMSC; Longeveron human mesenchymal stem cells

Latest Information Update: 25 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Longeveron
  • Developer Longeveron; University of Maryland, Baltimore; University of Miami
  • Class Antidementias; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Fatigue
  • Phase I/II Dilated cardiomyopathy
  • Phase I Alzheimer's disease; Congenital heart defects
  • Clinical Phase Unknown Metabolic syndrome

Most Recent Events

  • 23 Jan 2018 Efficacy data from phase I and phase II trials in Fatigue (Ageing frailty) released by Longeveron
  • 11 Nov 2017 Efficacy data from the POSEIDON-DCM phase I/II trial presented at the 90th Annual Scientific Sessions of the American Heart Association (AHA-2017)
  • 06 Nov 2017 Phase-II clinical trials in Fatigue (In the elderly) in Japan (IV) before November 2017 (Longeveron pipeline, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top